Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01341483 · ClinicalTrials.gov registry record
Incidence of Male Pudendal Artery Stenosis in Suboptimal Erections Study
A clinical trial, sponsored by Medtronic Endovascular.
- Terminated
- Registry status
- 19
- Enrollment target
NCT01341483: Clinical Trial study, sponsored by Medtronic Endovascular.
NCT01341483 is a clinical trial that was terminated before completion, run by Medtronic Endovascular. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01341483 was terminated before completion, sponsored by Medtronic Endovascular.
- TERMINATED
- Registry status
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the proportion of men with known or suspected coronary artery disease (CAD) and/or peripheral arterial disease (PAD) that have angiographic identifiable erectile related artery (ERA) atherosclerotic disease defined as at least one ERA stenosis greater than or equal to 50% (per core lab Quantitative Vascular Analysis - QVA).
Primary Outcome
Identifiable ERA disease is defined as at least one ERA stenosis greater than or equal to 50 percent (per core lab Quantitative Vascular Analysis - QVA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-03 |
Why NCT01341483 stopped before completion
NCT01341483 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01341483 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01341483 about?
NCT01341483 is a clinical study titled "Incidence of Male Pudendal Artery Stenosis in Suboptimal Erections Study". The purpose of this study is to determine the proportion of men with known or suspected coronary artery disease (CAD) and/or peripheral arterial disease (PAD) that have angiographic identifiable erectile related artery (ERA) atherosclerotic disease defined as at least one ERA stenosis greater than o...
What is the current status of trial NCT01341483?
This trial is currently terminated. The enrollment target is 19 participants. The study started on 2011-04. Estimated completion is 2012-03.
Who is sponsoring clinical trial NCT01341483?
This trial is sponsored by Medtronic Endovascular, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia